liu.seSök publikationer i DiVA
Ändra sökning
RefereraExporteraLänk till posten
Permanent länk

Direktlänk
Referera
Referensformat
  • apa
  • harvard1
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • oxford
  • Annat format
Fler format
Språk
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Annat språk
Fler språk
Utmatningsformat
  • html
  • text
  • asciidoc
  • rtf
Lenalidomide versus lenalidomide plus dexamethasone prolonged treatment after second-line lenalidomide plus dexamethasone induction in multiple myeloma
Karolinska Univ Hosp, Sweden.
Karolinska Univ Hosp, Sweden.
Sunderby Hosp, Sweden.
Karolinska Univ Hosp, Sweden; NSU, FL USA.
Visa övriga samt affilieringar
2018 (Engelska)Ingår i: Cancer Medicine, ISSN 2045-7634, E-ISSN 2045-7634, Vol. 7, nr 6, s. 2256-2268Artikel i tidskrift (Refereegranskat) Published
Abstract [en]

Lenalidomide (Len) plus dexamethasone (Dex) is approved for the treatment of relapsed or refractory multiple myeloma (RRMM). It is possible that single-agent Len may be effective as prolonged treatment regimen in RRMM once patients demonstrate an initial response to Len+Dex induction. Patients with RRMM who responded to first-line Len+Dex in an observational study (NCT01430546) received up to 24 cycles of either Len (25mg/day) or Len+Dex (25mg/day and 40mg/week) as prolonged treatment in a subsequent phase 2 clinical trial (NCT01450215). In the observational study (N = 133), median time to response was 1.7 (range 0.6-9.6) months. A complete response to all treatments received in both studies was observed in 11% of patients; very good partial response and partial response rates were 31% and 38%, respectively. Corresponding response rates in the subgroup of patients who did not enter the phase 2 trial (n = 71) were 3%, 18%, and 39%, respectively. Rates of disease progression at 2years in the phase 2 trial were 47% versus 31% for Len versus Len+Dex (P = 0.14). After 36months median follow-up in surviving patients, median time to progression was not reached with Len+Dex and was 24.9months (95% confidence interval 12.5-not calculable, P amp;lt; 0.001) with Len. Three-year OS among the total observational study population was 61% (95% CI, 52-69%). The corresponding rate among patients who entered the phase 2 clinical trial was 73% (95% CI, 60-83%) and was significantly lower among those patients who achieved PR but did not proceed into the phase 2 trial (55%; P = 0.01). In the phase 2 trial, OS was 73% in both treatment arms (P = 0.70). Neutropenia and thrombocytopenia were more common with prolonged (phase 2 trial) versus short-term (observational study) Len administration but remained manageable. Prolonged treatment with Len with or without Dex provides sustained, clinically relevant responses and demonstrates an acceptable safety profile.

Ort, förlag, år, upplaga, sidor
WILEY , 2018. Vol. 7, nr 6, s. 2256-2268
Nyckelord [en]
Clinical Trial; Lenalidomide; Multiple Myeloma
Nationell ämneskategori
Cancer och onkologi
Identifikatorer
URN: urn:nbn:se:liu:diva-149531DOI: 10.1002/cam4.1422ISI: 000435771000003PubMedID: 29673108OAI: oai:DiVA.org:liu-149531DiVA, id: diva2:1231062
Anmärkning

Funding Agencies|Celgene Corporation; Swedish Cancer Society

Tillgänglig från: 2018-07-05 Skapad: 2018-07-05 Senast uppdaterad: 2019-05-02

Open Access i DiVA

fulltext(355 kB)57 nedladdningar
Filinformation
Filnamn FULLTEXT01.pdfFilstorlek 355 kBChecksumma SHA-512
03f86d583dd30a6803d71d24772464ce82474b6bd310f3a1e6de2fc2c4f754c7b0e6cc486ddfe3fd3cb416e90aee67124da75707edf6cf9869e6f3732ea61d37
Typ fulltextMimetyp application/pdf

Övriga länkar

Förlagets fulltextPubMed

Personposter BETA

Ahlberg, Lucia

Sök vidare i DiVA

Av författaren/redaktören
Ahlberg, Lucia
Av organisationen
Hematologiska kliniken US
I samma tidskrift
Cancer Medicine
Cancer och onkologi

Sök vidare utanför DiVA

GoogleGoogle Scholar
Totalt: 57 nedladdningar
Antalet nedladdningar är summan av nedladdningar för alla fulltexter. Det kan inkludera t.ex tidigare versioner som nu inte längre är tillgängliga.

doi
pubmed
urn-nbn

Altmetricpoäng

doi
pubmed
urn-nbn
Totalt: 157 träffar
RefereraExporteraLänk till posten
Permanent länk

Direktlänk
Referera
Referensformat
  • apa
  • harvard1
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • oxford
  • Annat format
Fler format
Språk
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Annat språk
Fler språk
Utmatningsformat
  • html
  • text
  • asciidoc
  • rtf